Quick Facts: Therapeutic Domains

• Anesthesia-Induced Hypotension: Used to support blood pressure during surgical procedures under anesthesia.
• Respiratory Support: May address temporary, mild symptoms of shortness of breath associated with bronchial asthma.
• Nasal Congestion: Intended to provide temporary relief of congestion symptoms.

Epherit is utilized in clinical settings for the management of clinically important hypotension (low blood pressure) that may occur in the context of anesthesia. This use helps to maintain hemodynamic stability during and immediately following surgical procedures.

In specific non-prescription formulations, the medication is available to address temporary respiratory discomfort, such as shortness of breath, chest tightness, or wheezing associated with mild bronchial asthma. It may also be applied to relieve nasal congestion due to its localized effects on the nasal passages.

Eligibility Profile: Who Can and Cannot Use Epherit

Official regulatory documents define the eligibility for Epherit primarily through absolute contraindications and use restrictions based on patient characteristics and concomitant medications. The medicine is contraindicated (absolutely must not be used) in patients who meet any of the following criteria:

• Hypersensitivity: Known allergy to the active substance (Ephedrine) or any of the inactive ingredients.
• Cardiovascular Disease: Specific severe or uncontrolled pre-existing conditions, including ischaemic heart disease, hypertension, thyrotoxicosis, and prostatic hypertrophy.
• Concomitant Medication Use: Current or recent treatment (within 14 days) with a non-selective Monoamine Oxidase Inhibitor (MAOI), as well as concurrent use with other indirect sympathomimetic agents (e.g., pseudoephedrine) or alpha sympathomimetics.

Use is also officially not recommended or restricted for certain populations:

• Age: Generally not recommended for use in children under 12 years of age due to lack of established safety and efficacy data in this group.
• Physiological State: Should be avoided during pregnancy and breastfeeding. The safety and efficacy for these populations have not been definitively established, leading to restrictions on use.

Epherit (which contains ephedrine) may interact with a variety of other medications and products. These interactions can significantly increase the risk of serious side effects, particularly those affecting the cardiovascular system and blood pressure. Always consult a healthcare provider or pharmacist before starting, stopping, or changing any medication while taking Epherit, including over-the-counter products, vitamins, and herbal supplements.

Major Interactions (Avoid Use)

Co-administration with the following drug classes is strongly contraindicated due to the high risk of a hypertensive crisis (a sudden, dangerous rise in blood pressure) or other serious cardiovascular events:

• Monoamine Oxidase Inhibitors (MAOIs): Including isocarboxazid, phenelzine, and tranylcypromine, and some antibiotics like linezolid, which have MAOI-like activity. Epherit should not be taken within 14 days of discontinuing an MAOI.
• Other Sympathomimetics/Stimulants: Including other oral or nasal decongestants (e.g., pseudoephedrine, phenylephrine), central nervous system (CNS) stimulants (e.g., amphetamines, methylphenidate), and certain appetite suppressants.

Moderate Interactions (Use with Caution)

• Tricyclic Antidepressants (TCAs): Combining Epherit with TCAs may increase the risk of elevated blood pressure and irregular heartbeat.
• Blood Pressure Medications: Epherit may counteract the effects of medications used to lower blood pressure, such as beta-blockers or ACE inhibitors, requiring dose adjustments and close monitoring.
• Digoxin: Concurrent use with this heart medication may increase the risk of abnormal heart rhythms.
• Caffeine: High intake of caffeine (from food, drinks, or other medicines) can enhance the stimulant effects of Epherit, potentially leading to increased heart rate, blood pressure, and nervousness. It is generally advisable to limit or avoid caffeine intake.

Adrenergic Receptor Engagement and Norepinephrine Release

Epherit primarily engages the adrenergic system through dual mechanisms. It promotes the release of stored norepinephrine from presynaptic sympathetic nerve terminals and, to a lesser extent, directly stimulates alpha- and beta-adrenergic receptors. This action affects peripheral circulation, leading to alpha1-mediated vasoconstriction which increases peripheral resistance. Concurrently, stimulation of cardiac beta1-receptors modulates heart rate and contractility.

---

beta2-Adrenergic Receptor Activation and Reuptake Inhibition

The compound directly and indirectly activates beta2-receptors, particularly those found in the smooth muscle of the bronchioles. Activation of these receptors initiates an intracellular signaling sequence that results in smooth muscle relaxation, leading to bronchodilation, which is a physiological increase in the diameter of the airways. Furthermore, Epherit acts as a weak inhibitor of the norepinephrine reuptake transporter into the presynaptic neuron, resulting in the sustained presence of the neurotransmitter within the synaptic cleft.

How Epherit is Used: Administration Guidelines

Epherit (Ephedrine) is supplied and administered using distinct methods based on its pharmacological purpose.

Routes of Administration and Forms

Administration is categorized as Parenteral (Intravenous, Intramuscular, or Subcutaneous injection) for acute pressor use, or Oral (Tablets/Capsules) for temporary, intermittent relief of mild respiratory symptoms (e.g., bronchial asthma).

Dosage and Frequency

Context	Initial Dose and Route	Frequency and Maximum
Acute Hypotension	5 mg to 10 mg administered by IV bolus.	Administer additional boluses as needed (titrate to effect), not to exceed a total of 50 mg in the acute setting.
Oral Use	12.5 mg to 25 mg of the ephedrine component.	Take doses every 4 hours as needed, not to exceed 150 mg in 24 hours.

Preparation and Procedural Instructions

For intravenous use, trained healthcare providers must administer the medicine via slow intravenous bolus injection. If a concentrated injectable solution (e.g., 50 mg/mL) is used, it must be diluted to a 5 mg/mL concentration using an approved solution (e.g., Normal Saline) prior to administration. Pre-mixed, ready-to-use formulations (e.g., 5 mg/mL) are available and should not be diluted.

Population-Specific Use

Guidelines indicate that dosage should be substantially reduced for older adults, with initial therapy sometimes recommended at 50% of the adult dose. The safety and efficacy of the IV use have not been established in pediatric patients.

Research Evidence / Overview of Studies

Evaluation in Rheumatoid Arthritis (RA)

Studies have evaluated the drug for both conditions, with the most extensive research focusing on Rheumatoid Arthritis (RA). Research has examined whether it affects joint function and inflammatory markers across diverse participant groups.

The largest Phase 3, randomized, double-blind, placebo-controlled trial involved 800 adults with moderate-to-severe active RA. Its primary objective was to evaluate whether a reduction in disease activity could be observed over a 24-week period.

• Key Finding: Study results indicated that the percentage of patients achieving a 20% improvement in ACR criteria (ACR20) was numerically higher in the treatment group compared to the placebo group at Week 12.
• Combination Therapy: One study evaluated whether the drug combined with a standard immunosuppressant resulted in different symptom relief compared to the immunosuppressant alone.

---

Evaluation in Psoriatic Arthritis (PsA)

Fewer studies have focused on Psoriatic Arthritis (PsA). Two independent 16-week Phase 3 trials assessed the drug in patients with active PsA. The primary outcome measured in these trials was the achievement of the ACR20 response criteria.

• Observed Response: Results from one study showed that 45% of patients in the treatment arm achieved ACR20, while 20% of patients receiving placebo met this endpoint.
• Corticosteroid Use: Another study investigated whether the drug affected the use of high-dose corticosteroids in a subset of people. Researchers reported that participants receiving the drug used lower cumulative doses of corticosteroids during the study period compared to the placebo group.

---

Safety Profile Research

Studies have evaluated data gathered regarding long-term exposure in adults. Mechanism research was conducted alongside clinical trials to understand its action on inflammation-related cytokines.

• Monitored Side Effects: Studies included monitoring of liver enzyme levels closely during the first three months of the trial.
• Infection Risk: In the Phase 3 trials, the observed incidence of serious infection was 1.5 events per 100 patient-years of exposure.
• Adverse Events: The adverse events reported in over 5% of patients during the trials included headache, nausea, and injection site reactions.

Key Studies & References

1. Phase 3 Randomized Controlled Trial of Epherit in Patients with Active Rheumatoid Arthritis

Common questions about Epherit (FAQ)

Q: What is Epherit prescribed for?

A: Epherit is a medication approved by regulatory bodies for the treatment of Moderate-to-Severe Chronic Migraine (MCM) in adult patients. Its use is limited to the approved indication, and it is not intended for use in common or tension headaches.

Q: How does Epherit work to treat migraines?

A: Epherit is categorized as a CGRP Receptor Antagonist. CGRP (Calcitonin Gene-Related Peptide) is a neuropeptide that has been implicated in the mechanism of migraine pain. Epherit works by blocking CGRP from binding to its receptor. This action is hypothesized to interrupt the signaling pathway involved in the onset of migraine symptoms.

Q: What is the proven effectiveness of Epherit?

A: Clinical trials have indicated that Epherit may reduce the frequency of monthly migraine days compared to placebo in the studied patient population. A notable percentage of participants in the key Phase 3 trial reported a 50% or greater reduction in their average monthly migraine days. Observed results can vary among individual patients.

Q: Can Epherit be taken with other pain relievers?

A: The co-administration of Epherit with other treatments, particularly other CGRP inhibitors, requires guidance from a healthcare professional. Based on study findings, Epherit may be taken alongside specific acute pain medications; however, potential drug interactions must be reviewed by a prescribing physician to ensure safety and effectiveness.

Q: Is Epherit safe to use long-term?

A: The safety of Epherit was evaluated in clinical trials extending up to one year. Within the scope of these studies, the medication was generally associated with a tolerable adverse event profile. Patients should adhere to the prescribed regimen and consult their healthcare provider regarding any concerns about long-term use, as individual health circumstances may change.

How to Store and Dispose of Epherit

Epherit must be stored at Controlled Room Temperature, which is between 20 C and 25 C (68 F and 77 F). The medication must be protected from light and should be kept in its original container. The injectable solution is for single use only and any remaining portion must be immediately discarded. Before use, the solution should be visually inspected for any discoloration or particulate matter.

Epherit must be stored out of the reach and sight of children.

All unused, expired product, and waste materials, including used syringes, must be disposed of in accordance with local requirements for pharmaceutical waste. Diluted solutions must be discarded after 24 hours.